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AIMS
To evaluate congenital anomaly (CA)-medication exposure associations produced by the new EUROmediCAT signal detection
system and determine which require further investigation.
METHODS
Data from 15 EUROCAT registries (1995–2011) with medication exposures at the chemical substance (5th level of Anatomic
Therapeutic Chemical classification) and chemical subgroup (4th level) were analysed using a 50% false detection rate. After
excluding antiepileptics, antidiabetics, antiasthmatics and SSRIs/psycholeptics already under investigation, 27 associations were
evaluated. If evidence for a signal persisted after data validation, a literature review was conducted for prior evidence of human
teratogenicity.
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RESULTS
Thirteen out of 27 CA-medication exposure signals, based on 389 exposed cases, passed data validation. There was some prior
evidence in the literature to support six signals (gastroschisis and levonorgestrel/ethinylestradiol (OR 4.10, 95% CI 1.70–8.53;
congenital heart disease/pulmonary valve stenosis and nucleoside/tide reverse transcriptase inhibitors (OR 5.01, 95% CI 1.99–
14.20/OR 28.20, 95% CI 4.63–122.24); complete absence of a limb and pregnen (4) derivatives (OR 6.60, 95% CI 1.70–22.93);
hypospadias and pregnadien derivatives (OR 1.40, 95% CI 1.10–1.76); hypospadias and synthetic ovulation stimulants (OR 1.89,
95% CI 1.28–2.70). Antipropulsives produced a signal for syndactyly while the literature revealed a signal for hypospadias. There
was no prior evidence to support the remaining six signals involving the ordinary salt combinations, propulsives, bulk-forming
laxatives, hydrazinophthalazine derivatives, gonadotropin releasing hormone analogues and selective serotonin agonists.
CONCLUSION
Signals which strengthened prior evidence should be prioritized for further investigation, and independent evidence sought to
confirm the remaining signals. Some chance associations are expected and confounding by indication is possible.
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• There is insufficient information on the safety of the vast majority of medications when taken during pregnancy and more post-
marketing surveillance of medication safety in pregnancy is needed.
• Signal detection based on spontaneous adverse effect reporting is biased and incomplete.
WHAT THIS STUDY ADDS
• The EUROmediCAT database, comprising data from population-based EUROCAT congenital anomaly registries, can be used for
systematic signal detection and signal strengthening.
• Our results strengthen six congenital anomaly-medication exposure signals in the literature.
• We generated seven new signals which require independent confirmation as some may be chance findings.
Introduction
Congenital anomalies (CAs), structural or functional abnormal-
ities that are present from birth [1], are a major cause of infant
mortality, childhood morbidity and long-term disability [2].
They are a diverse group of disorders of prenatal origin and
can be caused by a wide range of factors such as genetics, envi-
ronmental agents, medications and physical conditions [3–5].
While a number of antenatal medication exposures are known
to cause CAs [6], there is insufficient information on the risks
and safety for the vast majority of medications [7]. The critical
period for most major CAs is during organogenesis, in the first
trimester of pregnancy [8]. It has been estimated that 22–54%
of pregnancies [9, 10] are exposed to prescription medications,
excluding vitamins and minerals, during this time period. As a
result, the lack of information in relation to the safety of
medication during human pregnancy is a serious public health
problem [11].
Typically, eligibility criteria for premarketing clinical tri-
als exclude high risk individuals such as pregnant women
[12]. The evaluation of medication safety in human preg-
nancy therefore relies on post-marketing surveillance to
detect medication safety signals [13]. As defined by theWorld
Health Organisation (WHO), a signal refers to ‘reported
information on a possible causal relationship between an
adverse event and a medication, the relationship being
unknown or incompletely documented previously’ [14].
Signals are detected when the observed number of reports
is higher than expected for a particular medication-event
combination [12, 15]. Such statistical signals are frequently
found because of the large number of comparisons made
and do not necessarily mean that a causal association is
present [12]. Even strong signals can be generated by various
forms of confounding [16], so once a signal is generated, signal
strengthening and signal evaluation are necessary in order to
reinforce or refute the potential signal [13, 16, 17]. While infor-
mation on true medication safety signals should not be
withheld from physicians and patients, false positive signals
may cause substantial harm if they limit access to safe medica-
tions [17].
Traditionally signal detection has relied on national or
international spontaneous reporting systems which pool
reports of adverse medication events provided by healthcare
providers, consumers and medication manufacturers [15].
Spontaneous report databases have a number of limitations
such as under-, over- and duplicate reporting, limited informa-
tion on concomitant medication or comorbidities and suscepti-
bility to bias [12–14]. To overcome some of these limitations,
programmes have been initiated to make use of large data pools
besides spontaneous reports such as healthcare databases and
disease registries [13, 18, 19]. EUROmediCAT’s population-
based reproductive pharmacovigilance system is based on the
European Surveillance of Congenital Anomalies (EUROCAT)
network. A statistical signal detection analysis was conducted
using the EUROmediCAT central database to find highly statis-
tically significant CA-medication exposure associations [20].
The aim of this paper is to describe the protocol used for evalu-
ation of the signals produced by the EUROmediCAT statistical
signal detection analysis, and to give the results of evaluation
of 27 CA-medication exposure associations to determine which
should be prioritized for further investigation.We do not report
here signals belonging to four medication groups which
wereseparately investigated as part of the EUROmediCAT
project: antiepileptic medications, insulin/insulin analogues,
antiasthmatic medications and selective serotonin reuptake
inhibitors and psycholeptics [21–24].
EUROmediCAT signal evaluation
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Methods
Dataset and statistical signal detection analysis
EUROCAT registries record all cases of major CA seen, among
live births, fetal deaths ≥20 weeks’ gestation and termination
of pregnancy for fetal anomaly (TOPFA) [25–27]. Births from
15 EUROmediCAT registries across 13 countries (1995–2011)
were used to create a signal detection dataset (see Supplemen-
tary Table 1 [20]). This included 14,950 infants with a CA, ex-
cluding genetic conditions1 or isolated congenital
dislocation of the hip, who were exposed to a medication in
the first trimester, excluding folic acid, minerals, vitamins
and/or topical medication [20], coded to the Anatomic Ther-
apeutic Chemical (ATC) classification system [28]. Data on
maternal medication exposures are mostly obtained from
prospectively recorded maternity records [29, 30].
The signal detection methodology used has been
described elsewhere [20]. In brief, a case-malformed control
approach was used where cases of a specific CA subgroup
[31] were compared with all other CAs in terms of exposure
to each specific medication. The signal detection analysis
was conducted using medications recorded at the 4th ATC
level (chemical subgroup) and the 5th ATC level (chemical
substance). Use of different ATC codes for the same medica-
tion and changes to ATC codes over time were taken into ac-
count. Medications with less than three exposed
fetuses/babies were excluded from the analysis. Any registry
with no exposures to the medication of interest, or cases of
the CA of interest, were also removed from each analysis.
Overall, 59 CA subgroups and 693 medication groups were
tested, resulting in 40,385 analyses. In order to limit the
number of false positive associations, multiple testing proce-
dures were implemented, using a 50% false discovery rate
(FDR), where the cut-off P-value for associations at the 5th
ATC level was 0.00040 and at the 4th ATC level was 0.0011
[20]. As the individual medications at the 5th ATC level all
contribute to the 4th ATC level group, if an association arose
at both the 4th and 5th ATC levels, the 5th ATC level associ-
ation was taken as the result. This analysis produced 11 CA-
medication exposure signals [20] which were from medica-
tion groups not already being investigated as part of the
EUROmediCAT project [32], i.e. excluding antiepileptics,
antidiabetics, antiasthmatics and SSRIs/psycholeptics.
A previous analysis of the same dataset without some of the
analytic refinements reported here (such as the amalgamation
of duplicate ATC codes) [33], and cut-off P-values for associa-
tions at the 5th and 4th ATC levels of 0.00048 and 0.0028
respectively, had identified an additional 16 signals. These orig-
inal signals were included for further analysis as a comparison of
the odds ratios (OR) and 95%CIs remained very similar between
the original and revised analyses (Figure 1 and Table 1), and
although the FDR P-value threshold was slightly higher, it is
not the sole criterion for identifying a potential association of
interest. When both sets of results were combined, there were
27 CA-medication exposure signals. Results are given combined
and separately.
Signal validation
Initially, the exposed cases for each of the 27 CA-medication
exposure associations were validated, in terms of diagnosis,
medication exposure and timing of exposure, with the local
registries.
The OR based on these validated data were then adjusted
for confounding by registry, i.e. where a registry may differ
in both their (recorded) exposure proportion and (recorded)
CA subgroup proportion in such a way as to produce artificial
relationships between the exposure and outcome. Adjust-
ment for registry was done by conducting a meta-analysis in
STATA/SE 12.1 using the fixed effect Mantel–Haenszel
method [34, 35]. Continuity corrections were made as per
the method by Sweeting et al. [36].
With the exception of chromosomal anomalies, most CAs
are not strongly associated with maternal age [37]. However,
gastroschisis, an abdominal wall defect, is associated with
young maternal age [38] and it was necessary to adjust the
gastroschisis-medication exposure association for maternal
age. This was done by stratifying the meta-analysis by mater-
nal age group [39], categorized as <20, 20–24, 25–29, 30–34,
35–39 and 40+.
Those CA-medication exposure associations which
persisted, when using validated data and adjusting for registry
effects, were considered validated statistical signals.
Signal description
The validated statistical signals were then described in detail
in terms of the signal ORs and 95% CIs, the adjusted ORs
and 95% CIs using validated data, the number of exposed
cases and the most prevalent concurrent medication1Chromosomal anomalies, genetic syndromes and skeletal dysplasias
Figure 1
Signal evaluation flow diagram
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exposures recorded among exposed cases. In addition, the
statistically significant CA-medication exposure associations
which failed to meet the FDR threshold (FDR <50%) but
which involved the same medication, or 3rd ATC level, expo-
sure were also noted.
Signal literature review
A literature review was then conducted, for the validated
statistical signals, by searching REPROTOX, TOXBASE, the
Developmental and Reproductive Toxicology Database
(DART) and PubMed. For those signals at the 5th ATC level,
this involved searching initially for the specific medication
and then for the 4th ATC level medication group. For signals
at the 4th ATC level a literature review was conducted for
both the medication group and each specific medication in
the group. REPROTOX and TOXBASE were searched using
the medication/group name alone. DART and PubMed were
searched using the name of the medication/group combined
with search terms for teratogen and CA (see Supplementary
Document 1 for more detail). The reference lists of relevant
articles were also searched. Cohort and case-control studies
were of particular interest but case reports/series were also
noted where available as the evidence was limited for some
medications. The available published evidence was catego-
rized according to the amount of evidence to support the
signal in the human literature, i.e. signal CA described in
the literature, teratogenicity leading to other CA described
in the literature, or no evidence of teratogenicity in the liter-
ature. When the evidence was based on case reports/series or
a single case-control or cohort study, the published evidence
was noted as minimal.
Ethical approval
Ethical approval for this study was provided by the University
of Ulster Nursing Research Governance Filter Committee.
Results
Signal validation
Out of the 27 original CA-medication exposure associations
14 (seven from the original and seven from the revised
analysis) were not validated as independent signals: one was
a duplicate signal as more than one formulation of the
medication is available (the combined contraceptive levonor-
gestrel and ethinylestradiol); for five CA-medication expo-
sure associations a proportion of the CA cases and/or first
trimester medication exposures could not be verified so that
the OR using validated data more than halved to less than
1.5; eight CA-medication exposure associations were
explained by confounding by registry.
This left 13 (nine from the original and four from the revised
analysis) validated unique CA-medication exposure signals
related to gastrointestinal medications (n = 4), antihyperten-
sives (n = 1), female sex hormones (n = 3), medications used in
infertility treatments (n = 2), antiretrovirals (n = 2) and selective
serotonin (5HT1) agonists (n = 1).
Signal description
The 13 statistical signals were based on between three and 89
confirmed CA cases with first trimester medication exposures
(Table 1).
Signal literature review
Of the 13 validated signals for which a literature review was
conducted, previous evidence in the literature was found for
six (Table 2).
Discussion
We have found 13 CA-medication exposure signals which
require further confirmation. There was evidence in the
literature, albeit conflicting at times, to support six of the 13
signals [40–64]. These six signals have been strengthened
and should be prioritized for further evaluation. Four of these
signals were related to sex hormones (gastroschisis and the
contraceptive levonorgestrel/ethinylestradiol; complete ab-
sence of a limb and pregnen (4) derivatives; hypospadias
and pregnadien derivatives; hypospadias and synthetic
ovulation stimulants). We also had as yet unvalidated data
that some other anomalies might be associated with these
medications. Sex hormone-based medications accounted for
24.8% of the medication exposures in the database [20]. The
other two of these signals were congenital heart defects and
pulmonary valve stenosis associated with
nucleoside/nucleotide reverse transcriptase inhibitors, anti-
virals used for HIV and chronic hepatitis. For all of these sig-
nals, the possibility of confounding by indication, or by co-
exposures, should be considered. The progestogens are used
to ‘support’ pregnancies at risk of early loss. It may be that
this leads to increasing survival of CA-affected fetuses [65].
Sub-fertile women have been found to have a higher risk of
having a child with a CA regardless of whether or not they re-
ceive infertility treatment [66–69], and this or other co-
exposures may confound the interpretation of medication
use related to subfertility or infertility [69]. Those receiving
antiviral treatment for HIV or hepatitis infection may have
other exposures leading to an increased risk of CAs [70].
However, the case-malformed control approach used in this
study will have negated this issue to some extent as the
comparison group also have CAs.
The only evidence that the antipropulsive antidiarrheals
may be teratogenic was a single report of an association with
hypospadias [71], rather than syndactyly as in our results.
These two anomalies are usually considered aetiologically
unrelated.
The remaining six statistical signals did not have supporting
evidence in the literature and should be confirmed in an inde-
pendent dataset. For selective serotonin agonists, a number of
previous studies have found no association with CA [72–81]
but thesewere too small tofind an anomaly as rare as congenital
constriction bands. Hydrazinophthalazine derivatives, antihy-
pertensives which act on arteriolar smooth muscle, have one
small previous negative study [82]. Other types of antihyperten-
sives, such as ace inhibitors, have been associated with an
increased risk of CA [83] but the underlying maternal hyperten-
sion also appears to play a role in the development of CA [84].
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ra
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).
A
re
tr
os
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d
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at
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os
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h
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b
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m
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m
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g
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at
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ra
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ra
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os
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e
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ra
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ra
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ra
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ra
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b
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at
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d
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ra
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d
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os
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p
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ra
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ra
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ra
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ra
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d
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at
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os
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d
al
lC
A
s
co
m
bi
ne
d
[8
2
].
G
0
3A
B0
3/
G
03
A
A
0
7
Le
vo
no
rg
es
tr
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d
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ad
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b
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ra
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re
la
ti
ng
to
le
vo
n
or
g
es
tr
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d
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ad
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ra
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b
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]
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os
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at
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os
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h
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].
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b
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at
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re
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ra
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b
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ac
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ra
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no
ro
ne
,
m
ed
ro
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ro
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d
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C
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b
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en
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)
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va
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s
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.
A
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ro
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)
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ra
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C
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d
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d
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.
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p
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ra
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b
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b
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at
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ro
xy
pr
og
es
te
ro
ne
(G
03
D
A
03
)
an
d
pr
og
es
te
ro
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].
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d
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at
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ca
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].
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b
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at
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b
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].
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p
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ro
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ra
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at
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ra
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b
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ra
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ro
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e
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p
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b
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ro
ge
st
er
o
ne
(G
03
D
B0
1)
[1
31
–
13
4]
.
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at
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ro
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c
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c
ov
u
la
tio
n
st
im
u
la
nt
s
ar
e
us
ed
in
in
fe
rt
ili
ty
tr
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at
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ra
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b
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at
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at
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at
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p
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p
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at
iv
e
[6
6]
.
A
n
as
so
ci
at
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os
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b
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b
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ra
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ra
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p
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While there are concerns about assisted reproduction in general
in relation toCA risk [85], and two of our other signals discussed
above are medications used in assisted reproduction, there is
only minimal case report evidence [86–89] relating to gonado-
tropin releasing hormone analogues, and none of these case
reports relate to laterality anomalies. Previous studies of the pro-
pulsives [90–97] have been negative regarding teratogenicity
and there is no evidence to support our finding. The ordinary
salts and bulk-forming laxatives are generally assumed to be
safe, have low bioavailablity, do not interfere with normal phys-
iologic salt balance and therefore were not specifically studied.
The signal detection methodology used in EUROmediCAT
was based on a 50% FDR. This means that half of the asso-
ciations found are expected to be chance associations, i.e.
not causal. Due to this uncertainty, and the difficulties of
interpretation discussed above, medication decisions
should not be made based on the CA-medication exposure
signals identified but should await the results of further
research.
Strengths and limitations
A strength of this study is the use of the EUROmediCAT
central database. EUROmediCAT’s international population-
based database contains detailed coding of all CAs [29] and
includes TOPFA cases which constitute a large proportion of
some CA [98]. The diagnosis of CAs is standardized across
the registries involved and will have ensured consistency in
the diagnosis [27]. There will also be much less under-
reporting and bias than in spontaneous reporting pharma-
covigilance systems as all major CAs are recorded in
EUROCAT, not just those which clinicians consider to be
important enough or potentially linked to a medication ex-
posure. While the EUROmediCAT database contains detailed
information on medications taken during the first trimester
of pregnancy, there is known underascertainment of some
medications [30, 99] but while this may reduce the sensitivity
of the system to detect certain teratogenic medications, it
should not lead to bias due to the use of malformed controls.
It was only possible to validate the data relating to the ex-
posed cases. This means that while the number of exposed
cases may have decreased, owing to errors found in data cod-
ing, the number of exposed controls will not have changed.
As a result, the data validation process could only decrease
the ORs. We found evidence that other anomalies were also
associated with the signal medications, but at lower levels of
statistical significance which did not surpass the FDR thresh-
old, and did not validate these data. However, data validation
for the main findings is a strength of this study.
The signal detection process used did not take prior litera-
ture into account during the statistical analysis [100] but
instead brought this in at the signal evaluation stage. In the
EUROmediCAT analyses of antiepileptics, antidiabetics, anti-
depressants and antiasthmatics [21–24], we first searched the
literature before evaluating existing signals and detecting
new signals. The signal detection process we report in this
paper is intended to be used in addition to the drug class by
drug class approach. It can be used to identify themost highly
significant associations in the database for drug classes not
otherwise undergoing analysis. We recognize that there may
be many other associations in the data that did not meetTa
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the FDR threshold but which are nevertheless of potential
interest. Indeed, this is shown by our evaluation of the 16
signals arising from the original signal detection analysis,
which included a number of associations reported previously
in the literature.
While the literature search was extensive, it is possible
that relevant articles may have been missed, particularly
negative evidence for a medication exposure when analysed
as one of many aetiological factors in a case-control study.
We were assessing whether previous literature existed but
did not conduct a meta-analysis of the evidence to date, and
this may lead to highlighting positive over negative evidence,
although all evidence found is presented. It was necessary to
search for each of the individual medications, rather than
the broader medication group, as the 4th ATC level, chemical
subgroup, was not always used in the literature or databases
and returned little or no information for some of the signals.
Without prior hypotheses about the mechanism of action, it
can also be difficult to decide how broadly to look for related
literature – for example there is a large literature on sex
hormones as a class, but much less related to specific sex
hormones. While positive evidence in the literature regard-
ing risk of all CAs combined could be considered supportive,
negative evidence is more difficult to interpret, as few medi-
cations increase the rate of all CAs combined, instead tending
to increase the rate of specific CAs [101].
As far as possible, changes over time in the ATC codes used
for particular medications were taken into account in both the
signal detection analysis and the signal evaluation. It is possible,
however, that some changes weremissed, potentially leading to
signals being missed as the exposed cases would be split across
more than one ATC code in the dataset.
Although all the cases were confirmed as first trimester
exposures, it is not known if these exposures actually oc-
curred during the critical period for CA development [8]. Sim-
ilarly there was no information available in terms of the doses
of medications taken for the majority of cases. If it was possi-
ble to identify a dose–response relationship or show exposure
during the critical period for development of the specific CAs,
this would provide support for a causal relationship [101].
Our protocol did not include assessment of biological plausi-
bility or possible teratogenic mechanisms [102]. Although
grouping of CA or of medications by potential teratogenic
mechanism has been advocated [3], we found this to be of
limited use as the same CAs are often related to a number of
potential mechanisms, and the current imperfect knowledge
of mechanisms is one of the drivers of signal detection in
postmarketing surveillance.
Conclusion
A statistical signal detection analysis was conducted using the
EUROmediCAT central database. Six signals had some prior
supporting evidence and these should be prioritized for
further investigation before being evaluated in relation to
clinical decision making. A further seven CA-medication
exposure signals were found which had no prior supporting
evidence and these need to be confirmed in independent
datasets.
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